MeritValue

Silo Pharma, Inc.

SILOdata completeness 75%12 fiscal years on file

Data notes: no data for concept 'capex'; no data for concept 'totalDebt'

The thesis, from the filings

Silo Pharma, Inc. earns about -210% on invested capital, but has diluted owners by 337% over 5 years — worth asking whether the growth reaches owners. The cash-flow models don't apply cleanly here — the ledger says why below.Whether it’s worth owning at today’s price is the last question — and yours to answer, below.

i. The business — what you’d actually own
FigureFY 2021FY 2022FY 2023FY 2024FY 2025
Revenue$1,2101$72,1022$72,1023$72,1024$72,1024
Net income$3.9M5−$3.91M6−$3.7M7−$4.39M8−$4.23M8
Operating cash flow−$2.28M9−$3.5M10−$3.22M11−$3.83M12−$4.66M12
Capital expenditure—————
Free cash flow (derived)—————
Total debt—————
Cash & equivalents$9.84M13$11.4M14$3.52M15$3.91M16$4.75M16
Diluted shares1.9M2.3M3.1M3.7M8.4M

Superscripts are receipts. Each links to the SEC filing the number came from (full list at the bottom).

ii. Your slice — ownership made literal
If you owned
shares
Net assets behind them
$7.52
your share of equity
Profit it earned you last year
−$5.04
Free cash flow it threw off
—
Debt you’d be carrying
—

10 shares is a claim on $7.52 of net worth that earned you −$5.04 last year.

iii. Is this a good business?
Moat signal · return on invested capital
-210% avg · 5y
FY21 —FY22 —FY23 -108%FY24 -308%FY25 -215%

It earned an average -210% on invested capital over 5 years. Compare that to what it costs to fund the business.

seeing a moat in the numbers →
Management signal · capital allocation
+337% shares · 5y

Share count is up 337% over 5 years — owners have been diluted. Worth asking what they got for it.

reading capital allocation →

Signals, not verdicts — read from the filings above. Numbers don’t prove a moat; they show its footprint. You decide.

iv. What it’s worth — engine v0.1.0
DCF · Growth Exit 10Y
not applicable
only 0 years of FCF (need ≥3) — model not applicable
DCF · Growth Exit 5Y
not applicable
only 0 years of FCF (need ≥3) — model not applicable
Earnings Power Value
not applicable
normalized (5y-median) earnings non-positive — EPV undefined
Graham Number
not applicable
diluted EPS missing or non-positive — Graham Number undefined

Different models answer different questions — which to trust when →

Sources — the receipts
  1. 10-K · period ending 2021-12-31 · accession 0001213900-23-022813 (InterestAndDividendIncomeOperating)
  2. 10-K · period ending 2022-12-31 · accession 0001213900-24-025615 (Revenues)
  3. 10-K · period ending 2023-12-31 · accession 0001013762-25-004139 (Revenues)
  4. 10-K · period ending 2024-12-31 · accession 0001213900-26-035576 (Revenues)
  5. 10-K · period ending 2021-12-31 · accession 0001213900-23-022813 (NetIncomeLoss)
  6. 10-K · period ending 2022-12-31 · accession 0001213900-24-025615 (NetIncomeLoss)
  7. 10-K · period ending 2023-12-31 · accession 0001013762-25-004139 (NetIncomeLoss)
  8. 10-K · period ending 2024-12-31 · accession 0001213900-26-035576 (NetIncomeLoss)
  9. 10-K · period ending 2021-12-31 · accession 0001213900-23-022813 (NetCashProvidedByUsedInOperatingActivities)
  10. 10-K · period ending 2022-12-31 · accession 0001213900-24-025615 (NetCashProvidedByUsedInOperatingActivities)
  11. 10-K · period ending 2023-12-31 · accession 0001013762-25-004139 (NetCashProvidedByUsedInOperatingActivities)
  12. 10-K · period ending 2024-12-31 · accession 0001213900-26-035576 (NetCashProvidedByUsedInOperatingActivities)
  13. 10-K · period ending 2021-12-31 · accession 0001213900-23-022813 (CashAndCashEquivalentsAtCarryingValue)
  14. 10-K · period ending 2022-12-31 · accession 0001213900-24-025615 (CashAndCashEquivalentsAtCarryingValue)
  15. 10-K · period ending 2023-12-31 · accession 0001013762-25-004139 (CashAndCashEquivalentsAtCarryingValue)
  16. 10-K · period ending 2024-12-31 · accession 0001213900-26-035576 (CashAndCashEquivalentsAtCarryingValue)